An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Esbriet

Chemical Namepirfenidone
Dosage FormCapsule/Tablet (oral; 267 mg/267 mg, 801 mg)
Drug ClassMiscellaneous
SystemRespiratory
CompanyGenentech Inc.
Approval Year2014

Indication

  • For the treatment of idiopathic pulmonary fibrosis (IPF).
Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Esbriet (pirfenidone) Prescribing Information2014Genentech USA, Inc., South San Francisco, CA
Document TitleYearSource
Pirfenidone for treating idiopathic pulmonary fibrosis.2018NICE
Document TitleYearSource
Systematic review and meta-analysis of pirfenidone, nintedanib, and pamrevlumab for the treatment of idiopathic pulmonary fibrosis.2020Annals of Pharmacotherapy
Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis.2019Journal of Drug Assessment
Systematic review and network meta-analysis of idiopathic pulmonary fibrosis treatments.2017Journal of Managed Care and Specialty Pharmacy
Drug treatment of idiopathic pulmonary fibrosis systematic review and network meta-analysis. 2016Chest
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.2016BMC Medicine
Document TitleYearSource
German guideline for idiopathic pulmonary fibrosis - update on pharmacological therapies 2017.2018Pneumologie (Stuttgart, Germany)